- >
- Blog
- >
- Pharmaceutical Technology
Soluble drug APIs are now the exception, not the rule. An article at PharmTech by Felicity Thomas (Looking Beyond the Solubility Horizon) caught my eye recently as it discussed a…
This month, I managed to catch up on some of the industry articles I’ve been waiting to read which were relevant to APIs and pharma manufacturing generally. Here are a…
The healthcare industry is driven by scientific innovation, often in response to various public health crises. But while science & discovery often leap forward, the physical act of manufacturing a…
I read an article at PharmTech at the tail end of 2016 that I thought was quite interesting, and it reflects Neuland’s position on regulatory agencies & issues. The article…
A recent market report on APIs by Future Market Insights (FMI) paints a generally rosy economic picture of the industry over the next decade, but in this case the report’s…
In a recent issue of PharmTech, Agnes Shanley wrote an article on the specialty markets and services driving the growth of APIs in which we were featured. For me, the…
I’ve been trying to get caught up on some reading this month, and thought I’d put together a roundup of interesting articles I’ve run across recently. Grading GDUFA, at Contract…
I was interviewed back in April for a Pharmaceutical Technology (PharmTech) article about demand drivers for small-molecule APIs. The article by Agnes Shanley – Pharma APIs: It’s Still a Small…
In this month’s issue of PharmTech, team members at Neuland’s R&D Center in Hyderabad published a peer-reviewed article on the analysis and management of impurities in the drug Febuxostat. Febuxostat, a…
Related to our (persistent!) emphasis on regulatory excellence and complex chemistry capabilities, team members from Neuland Lab’s Analytical Research & Development Department at our R&D Centre developed and validated a…
